US-based developer of ultra-sensitive diagnostic platform Quanterix has launched its next-generation ultrasensitive immunoassay platform, Simoa 2.0.
In addition to addressing many customer requests, Simoa 2.0 includes multiple improvements to assay performance, hardware and software refinements and overall instrument usability.
The Simoa platform uses single molecule measurements to access previously undetectable proteins as well as offers significant benefits to both research and clinical testing applications.
With a simple upgrade procedure, the company will offer Simoa 2.0 improvements to all of its current customers.
The company noted that the improvements will be offered at no cost to ensure all users can benefit from the upgrades without any additional investment or interruption of their research.
The new improvements will include several hardware and software advances, as well as comprehensive training programme that will allow customers to improve overall performance, reliability and ease of use.
Quanterix CEO and executive chairman Kevin Hrusovsky said: "We have experienced rapid adoption of Simoa since our launch last year and have listened carefully to our customers' feedback on our 'game changing' fully-automated, ultrasensitive protein detection platform.
"Based on feedback, we have made an unprecedented investment to further improve the platform, including increasing assay robustness, improving multiplex capabilities, reducing sample size and enhancing overall usability of the technology."
"We are providing these important advances at no charge to our existing customers and have incorporated these developments into our Simoa 2.0 offering.
"We are excited to launch this new system and look forward to hearing customer reaction at our upcoming San Francisco customer forum."
In June, the company had commercially introduced multiplex panels, which allows users to develop their own multiplex assays using its ultra-sensitive Simoa technology.
The company has also launched multiplex homebrew kit that allows users to use their own antibody pairs to develop custom multiplex Simoa panels.